© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 13, 977-978,
July 4, 2001
© 2001 Oxford University Press
NEWS |
Awards, Appointments, Announcements
Five scientists whose research ultimately led to the development of STI571 were awarded the 13th annual Warren Alpert Foundation Scientific Prize at a ceremony at Boston.David Baltimore, Ph.D., president and professor of biology at the California Institute of Technology, and Owen N. Witte, M.D., Howard Hughes Medical Institute investigator and professor of microbiology, immunology and molecular genetics at the University of California at Los Angeles and Jonsson Comprehensive Cancer Center, were recognized for the basic science investigations that characterized the genetic pathway to CML.
For their preclinical work that led to the creation of STI571, the Alpert Foundation honored Alex Matter, M.D., head of oncology research, Novartis Pharma AG, and Nicholas B. Lydon, Ph.D., formerly of Novartis and now vice president for small molecule drug discovery at Amgen Inc.
Brian J. Druker, M.D., professor of medicine at Oregon Health Sciences University, was recognized for both his preclinical work and clinical trial investigations.
|
The Foundation will divide among the winners a $150,000 award.
Each year the committee recognizes creative research that has dramatically affected the human condition.
Mundy Named
The Cancer Therapy and Research Center, San Antonio, has named Gregory R. Mundy, M.D., the SBC communications chair and director of the CTRC Institute for Drug Development.
Mundy will keep his positions at the University of Texas Health Science Center at San Antonio as professor of bone and mineral metabolism, head of the Division of Endocrinology and Metabolism, and assistant dean for clinical research.
Part of the CTRC, the Institute for Drug Development is a private, nonprofit, medical research organization whose mission is to develop new treatments for patients with cancer through the integration of research programs in the basic, translational, and clinical sciences.
Surgeon Appointed
Thoracic surgeon Joseph S. Friedberg, M.D., has been named chief of the newly created Division of Thoracic Surgery at Thomas Jefferson University Hospital, Philadelphia.
|
Friedberg came to Jefferson from the Hospital of the University of Pennsylvania in Philadelphia, where he served as a thoracic surgeon in the Division of Cardiothoracic Surgery and as an assistant professor of surgery at the University of Pennsylvania School of Medicine.
Berman Elected
Michael L. Berman, M.D., has been elected president of the Society of Gynecologic Oncologists.
Berman is a professor in the Department of Obstetrics and Gynecology, in the Division of Gynecologic Oncology at the University of California Irvine Medical Center.
He began his term in March 2001, succeeding Carolyn Runowicz, M.D.
Denison Named
Grant Denison Jr. has been named president and chief executive officer of Genetronics Biomedical Ltd., Toronto.
Prior to joining Genetronics, he was chairman and CEO of BioMarin Pharmaceutical Inc. Denison will also keep his position on the Genetronics board of directors.
Falkner Appointed
Roswell Park Cancer Institute, Buffalo, N.Y., has appointed Karen L. Falkner, Ph.D., as program coordinator in the Department of Cancer Prevention, Epidemiology, and Biostatistics.
Falkner will supervise a study protocol for a population-based case–control study of childhood leukemia in Belarus.
Falkner is an assistant research professor in the Department of Social and Preventive Medicine at the University at Buffalo.
Higgins Named
Arthur J. Higgins has been named president and chief executive officer of Enzon Inc., Piscataway, N.J.
Prior to joining Enzon, Higgins was president of the Pharmaceutical Products Division of Abbott Laboratories.
Enzon is a biopharmaceutical company that develops therapeutics that use its drug delivery and targeting technologies.
Candidates Sought
The Cure For Lymphoma Foundation is seeking candidates for its 2002–04 Two-Year Fellowship Program. The intent of the CFL Fellowship is to encourage applicants to pursue careers in lymphoma basic, translational, and clinical research. Research may be laboratory or clinic based, but the results must be relevant to the treatment of lymphoma.
The fellowships provide a salary of $45,000 during the first year and $50,000 during the second year and $5,000 each year for the research project. Applicants must be fellows or junior faculty at or below the level of assistant professor at the start of the award period and hold a M.D., Ph.D., or equivalent degree. Applicants must be affiliated with a sponsoring institution in the U.S. for the duration of the CLF grant.
The application deadline is October 1, 2001. Awards will be announced in February 2002 and will begin in July 2002.
Applications and further information may be downloaded from CFL’s Web site at http://www.cfl.org/research.cfm or by contacting: Fran Morris, director, Medical & Scientific Outreach, Cure For Lymphoma Foundation, 215 Lexington Ave., New York, NY 10016; Tel: 212-213-9595, Fax: 212-213-1987, e-mail: fmorris{at}cfl.org.
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||